{"title":"Development of therapeutic agents for older patients with acute myelogenous leukemia.","authors":"Christopher S Hourigan, Judith E Karp","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Acute myelogenous leukemia (AML) is a disease more common in older patients than in the young. It is increasingly recognized that conventional cytotoxic chemotherapies used in children and young adults may not be appropriate in older adults because of diverse host- and disease-biology factors. This review highlights some of the most promising new treatment options that are being evaluated for older patients with AML. These options include CPX-351 (Celator Pharmaceuticals Inc), a unique liposomal formulation of a fixed ratio of cytarabine and daunorubicin; timed sequential therapy with the CDK inhibitor alvocidib (flavopiridol; sanofi-aventis/NCI); the second-generation purine nucleoside analog clofarabine; the farnesyltransferase inhibitor tipifarnib (Johnson & Johnson Pharmaceutical Research and Development LLC); and the DNA methyltransferase inhibitors decitabine and azacitidine.</p>","PeriodicalId":10978,"journal":{"name":"Current opinion in investigational drugs","volume":" ","pages":"669-77"},"PeriodicalIF":0.0000,"publicationDate":"2010-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699173/pdf/nihms744846.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in investigational drugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Acute myelogenous leukemia (AML) is a disease more common in older patients than in the young. It is increasingly recognized that conventional cytotoxic chemotherapies used in children and young adults may not be appropriate in older adults because of diverse host- and disease-biology factors. This review highlights some of the most promising new treatment options that are being evaluated for older patients with AML. These options include CPX-351 (Celator Pharmaceuticals Inc), a unique liposomal formulation of a fixed ratio of cytarabine and daunorubicin; timed sequential therapy with the CDK inhibitor alvocidib (flavopiridol; sanofi-aventis/NCI); the second-generation purine nucleoside analog clofarabine; the farnesyltransferase inhibitor tipifarnib (Johnson & Johnson Pharmaceutical Research and Development LLC); and the DNA methyltransferase inhibitors decitabine and azacitidine.
急性髓性白血病(AML)是一种老年患者比年轻人更常见的疾病。越来越多的人认识到，由于不同的宿主和疾病生物学因素，用于儿童和年轻人的传统细胞毒性化疗可能不适用于老年人。本综述重点介绍了一些正在评估的老年AML患者最有希望的新治疗方案。这些选择包括CPX-351 (Celator Pharmaceuticals Inc)，一种独特的阿糖胞苷和柔红霉素固定比例的脂质体制剂;CDK抑制剂alvocidib (flavopiridol;赛诺菲-安万特/ NCI);第二代嘌呤核苷类似物氯法拉滨;法尼基转移酶抑制剂tipifarnib (Johnson & Johnson Pharmaceutical Research and Development LLC);以及DNA甲基转移酶抑制剂地西他滨和阿扎胞苷。
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
